{"version":"1.0","provider_name":"IRLAB","provider_url":"https:\/\/irlab.se\/sv\/","title":"IRL1117 - IRLAB","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"43AAmAT2rR\"><a href=\"https:\/\/irlab.se\/sv\/projektportfolj\/irl1117\/\">IRL1117<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/irlab.se\/sv\/projektportfolj\/irl1117\/embed\/#?secret=43AAmAT2rR\" width=\"600\" height=\"338\" title=\"\u201dIRL1117\u201d &ndash; IRLAB\" data-secret=\"43AAmAT2rR\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/irlab.se\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"IRL1117 L\u00e4kemedelskandidaten IRL1117 utvecklas som en oral behandling f\u00f6r grundsymtomen av Parkinson, att tas en g\u00e5ng om dagen, utan att orsaka de besv\u00e4rliga komplikationer som dagens standardbehandling med levodopa ger upphov till. Utvecklingen mot kliniska studier har p\u00e5b\u00f6rjats f\u00f6r IRL1117. L\u00e4kemedelskandidaten IRL1117 kommer att utvecklas som en oralt administrerad behandling f\u00f6r grundsymtomen av Parkinson, att [&hellip;]"}